Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01109173 · ClinicalTrials.gov registry record · Phase 3
Confirmatory Study Nepafenac 0.3%
A Phase 3 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,120
- Enrollment target
NCT01109173 is a Phase 3 study that has completed, run by Alcon Research. The registered enrollment target is 2,120 participants.
The verdict
NCT01109173, a Phase 3 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,120 participants
- Enrollment target
Study Summary
The purpose of this study was to assess the safety and efficacy of an investigational eye drop intended for the prevention and treatment of inflammation (swelling and redness) and pain in the eye after cataract extraction.
Interventions
- DRUG Nepafenac Ophthalmic Suspension, 0.3%
- DRUG Nepafenac Ophthalmic Suspension, 0.1%
- OTHER Nepafenac Ophthalmic Suspension 0.3% Vehicle
- OTHER NEVANAC Vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,120 participants |
| Start Date | 2010-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01109173
The ClinicalTrials.gov registry entry for NCT01109173 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Nepafenac Ophthalmic Suspension, 0.3% is the first listed.
NCT01109173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01109173 about?
NCT01109173 is a clinical study titled "Confirmatory Study Nepafenac 0.3%". The purpose of this study was to assess the safety and efficacy of an investigational eye drop intended for the prevention and treatment of inflammation (swelling and redness) and pain in the eye after cataract extraction.
What is the current status of trial NCT01109173?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,120 participants. The study started on 2010-06.
What interventions are being tested in trial NCT01109173?
The interventions under investigation include: Nepafenac Ophthalmic Suspension, 0.3% (DRUG), Nepafenac Ophthalmic Suspension, 0.1% (DRUG), Nepafenac Ophthalmic Suspension 0.3% Vehicle (OTHER), NEVANAC Vehicle (OTHER).
Who is sponsoring clinical trial NCT01109173?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.